Cancer Drugmaker Parabilis Seeks $475 Million in US IPO
Parabilis Medicines, a clinical-stage cancer drug developer, is seeking to raise $475 million in an initial public offering.
By Avalon Pernell ยท Bloomberg Markets
Parabilis Medicines, a clinical-stage cancer drug developer, is seeking to raise $475 million in an initial public offering.